|Bid||292.90 x 0|
|Ask||292.85 x 0|
|Day's range||291.65 - 293.55|
|52-week range||256.05 - 335.85|
|Beta (5Y monthly)||0.19|
|PE ratio (TTM)||18.87|
|Earnings date||27 July 2023|
|Forward dividend & yield||9.50 (3.28%)|
|Ex-dividend date||16 Mar 2023|
|1y target est||364.36|
Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis have been highlighted in this Industry Outlook article.
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Roche (RHHBY) and Novartis (NVS) are worth retaining in your portfolio.
Kodiak (KOD) focuses on completing ongoing studies on tarcocimab for several retinal indications. However, competition in the market and the lack of other candidates in the pipeline are concerns.
Key Insights The considerable ownership by retail investors in Roche Holding indicates that they collectively have a...
Basel, 26 May 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will be presenting new data on six approved and investigational medicines across ten cancer types at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, held 2 – 6 June. Highlights include new data spanning treatments for lymphoma and hepatocellular carcinoma (HCC): Developing new treatment options for people with blood cancers Extended follow-up data for Columvi® (glofitamab) of almost two years (20 months) from the pivot
The FDA extends the review period for Sarepta's (SRPT) BLA for DMD gene therapy by almost four weeks to Jun 22. The agency may limit the use of the therapy in children aged between four and five.
Shares of Rain Oncology (NASDAQ: RAIN) were down 87% Monday afternoon after the precision oncology company released top-line results for its lead therapy, milademetan, to treat dedifferentiated liposarcoma, a type of cancer affecting fatty tissue, usually in the arms and legs. Rain said that milademetan, an inhibitor of the MDM2-p53 complex that reactivates p53, a known tumor inhibitor, taken orally, did not meet its primary endpoint of efficacy in a phase 3 trial to treat patients with dedifferentiated (DD) liposarcoma (LPS). Based on the disappointing results, Rain said it does not plan to pursue further development of the therapy to treat DD LPS.
Regeneron (REGN) loses some of its gains as sales of its lead drug, Eylea, decline. Nevertheless, Dupixent sales boost the top line.
FDA panel votes in favor of Pfizer's (PFE) experimental maternal RSV vaccine. FDA approves AbbVie's (ABBV) Rinvoq for Crohn's Disease.
Roche's (RHHBY) investigational oral fenebrutinib meets its primary and secondary endpoints in the phase II FENopta study.
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will be showcasing innovative laboratory solutions and digital diagnostics through - "Innovation Past, Present and Future" at this year's WorldLab-EuroMedLab 2023 in Rome, Italy, 21-25 May. Attendees will have the opportunity to experience first-hand Roche's latest technological advancements in lab automation, serum work area, molecular and point of care solutions and find out more about how the company is transforming patient care throu
SOUTH SAN FRANCISCO, Calif., May 17, 2023--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase II FENopta study evaluating investigational oral fenebrutinib in adults with relapsing forms of multiple sclerosis (RMS). The study met its primary and secondary endpoints, showing oral fenebrutinib significantly reduced magnetic resonance imaging (MRI) markers of MS disease activity in the brain compared to placebo. Additionally, pre-cli
Fenebrutinib is an investigational, potent and highly selective oral Bruton’s tyrosine kinase (BTK) inhibitor, the only reversible BTK inhibitor currently in Phase III multiple sclerosis (MS) trialsPhase II study met its primary and secondary endpoints by reducing the total number of new gadolinium-enhancing T1 brain lesions and significantly reducing the total number of new or enlarging T2 brain lesions compared to placeboThe safety profile of fenebrutinib was consistent with previous and ongoi
The FDA's CTGTAC narrowly recommends granting accelerated approval to Sarepta's (SRPT) DMD gene therapy. A final decision from the agency is expected by the end of this month.
Bayer (BAYRY) announces mixed Q1 results. AstraZeneca's (AZN) Ultomiris gets approval for a new rare disease indication in the EU.
Halozyme (HALO) first-quarter earnings and revenues miss estimates. The company reiterates its guidance for 2023.
SOUTH SAN FRANCISCO, Calif., May 09, 2023--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Vabysmo® (faricimab-svoa) for the treatment of macular edema following retinal vein occlusion (RVO). The sBLA is based on results from the Phase III BALATON and COMINO studies that demonstrated treatment with Vabysmo provided early and sustai
Acceptance based on two phase III studies that demonstrated early and sustained vision improvement with Vabysmo, meeting primary endpoint of non-inferiority compared to afliberceptApplication was further supported by data showing Vabysmo achieved rapid and robust drying of retinal fluid If approved, RVO would be the third indication for Vabysmo in addition to neovascular or ‘wet’ age-related macular degeneration (nAMD) and diabetic macular edema (DME)Vabysmo is currently approved in 60 countries
When we invest, we're generally looking for stocks that outperform the market average. Buying under-rated businesses is...
By Vlad Schepkov
The Institute of Human Biology aims to better predict which drug candidates are safe and most effective in patients by evolving and increasing the use of human model systems. Human model systems are miniature living 'replicas' of human tissues and organs that also have the potential to reduce reliance on animal testing. The institute brings together scientists from academia and industry to lead the broad adoption of human model systems in pharmaceutical R&D as well as in clinical practice. Basel
Sarepta (SRPT) delivers narrower-than-expected loss per share in first-quarter 2023. Total revenues beat estimates on the back of strong product sales growth during the quarter.
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphomaThe recommendation is based on results from the phase I/II NP30179 study, where Columvi given as a fixed course induced early and long-lasting complete responses in people with heavily pre-treated or refractory diffuse large B-cell lymphoma1Columvi is part of Roche’s industry-leading CD20xCD3 T-cell-engaging bispecific development programme, which
Roche's (RHHBY) performance in first-quarter 2023 is pretty ho-hum as COVID-19-test sales continue to decline.
Basel, 26 April 2023 As expected, significantly lower demand for COVID-19 tests leads to a decrease in Group sales (-3%1 at constant exchange rates [CER] and -7% in Swiss francs); excluding this effect, Group sales grow 8%Pharmaceuticals Division sales up 9%; strong demand for newer medicines; Vabysmo for severe eye diseases is already the strongest growth driverDiagnostics Division base business grows 4%, while divisional sales are 28% lower due to exceptionally high demand for COVID-19 tests i